Table of Contents

Quick answer

Eloralintide vs cagrilintide is a comparison of two once-weekly amylin drugs that are still in clinical trials for weight loss. Eloralintide, from Eli Lilly, targets amylin receptors selectively, while cagrilintide, from Novo Nordisk, also acts on related calcitonin receptors. In separate trials, eloralintide alone led to up to 20.1% average weight loss at 48 weeks and cagrilintide alone to 11.8% at 68 weeks, but the two have never been tested head to head, and neither is approved.

Takeaways

  • Both drugs copy amylin, a fullness hormone your pancreas releases with insulin. Neither is a GLP-1 drug.
  • Eloralintide is a selective amylin receptor agonist. Cagrilintide is non-selective, acting on amylin and calcitonin receptors.
  • Eloralintide’s best Phase 2 result was larger than cagrilintide’s best standalone result, but the trials differed in length, dose and design, so they cannot be compared directly.
  • Cagrilintide is closer to market as part of CagriSema, which is under FDA review with a decision expected in Q4 2026.
  • Neither drug is sold. Approved options such as Wegovy and Zepbound are available now with a prescription.

Eloralintide vs Cagrilintide at a Glance

The two drugs belong to the same class but differ in who makes them, which receptors they target and how far along they are. This table sums up what has been published as of October 28, 2026.

At a Glance

DetailEloralintideCagrilintide
DeveloperEli LillyNovo Nordisk
Receptors targetedAmylin receptors (selective)Amylin and calcitonin receptors (non-selective)
How it is given in trialsOnce-weekly injectionOnce-weekly injection
Best standalone weight loss reportedUp to 20.1% at 48 weeks (Phase 2)11.8% at 68 weeks (Phase 3 sub-analysis)
Combination in developmentEloraTZP (with tirzepatide)CagriSema (with semaglutide)
StatusPhase 3 trials ongoing; not approvedCagriSema under FDA review; not approved

If you are new to this drug class, our guide to what an amylin receptor agonist is explains how amylin works in plain English.

How Eloralintide and Cagrilintide Work Differently

Both drugs work mainly by helping you feel full sooner, so you eat less. The main difference is which receptors they switch on. Lilly’s discovery paper on eloralintide describes eloralintide as selective for amylin receptors and cagrilintide as non-selective, meaning it also activates calcitonin receptors, close relatives of the amylin receptor.

Lilly designed eloralintide this way on purpose. When it announced its Phase 2 results, the company said it believes molecule specificity is important in this class. In rat studies described in the same discovery paper, eloralintide caused less nausea-like behavior than cagrilintide.

That animal finding is interesting, but it is not proof that people will feel the same difference. No published trial has given eloralintide and cagrilintide to people side by side.

Weight Loss Results: What the Trials Show

In separate trials, eloralintide alone produced more average weight loss than cagrilintide alone, but these results come from different studies and cannot be ranked directly. Here is what each trial reported for people who stayed on treatment.

Trial Results Side by Side

TrialPeople enrolledLengthAverage weight loss vs placebo
Eloralintide Phase 2263 adults without type 2 diabetes48 weeks9.5% to 20.1%, depending on dose, vs 0.4%
Cagrilintide Phase 2706 adults without diabetes (all dose groups)26 weeks6.0% to 10.8%, depending on dose, vs 3.0%
Cagrilintide alone in REDEFINE 1 (Phase 3)Adults with obesity or overweight, without diabetes68 weeks11.8% vs 2.3%

The eloralintide figures come from Lilly’s Phase 2 eloralintide results. The cagrilintide figures come from the Lancet report on the cagrilintide Phase 2 trial and Novo Nordisk’s REDEFINE 1 results for cagrilintide alone.

Why not call eloralintide the winner? A few reasons:

  • Different trial lengths. Weight loss usually keeps building for months, so a 26-week result and a 48-week result are not on the same footing.
  • Different doses. Eloralintide’s top result came from its 9 mg dose. Cagrilintide’s Phase 3 data used a 2.4 mg dose, and its higher 4.5 mg dose was only tested for 26 weeks.
  • Different trial stages. Eloralintide’s numbers come from a 263-person Phase 2 trial. Cagrilintide has Phase 3 data from a much larger program.

In the cagrilintide Phase 2 trial, its 4.5 mg dose also beat liraglutide 3.0 mg, an older GLP-1 weight loss drug, by 10.8% to 9.0% at 26 weeks, according to the Lancet trial report.

GOOD TO KNOW

The doses in this section come from research studies and are listed for information only. Neither eloralintide nor cagrilintide has an approved dose. Talk to your prescriber about any weight loss medicine before starting or changing treatment.

Side Effects and Tolerability Compared

Both drugs mainly cause stomach-related side effects, such as nausea, and these were mostly mild to moderate in trials. Eloralintide also caused fatigue more often than placebo at higher doses.

Side Effects Side by Side

DetailEloralintide (Phase 2, 48 weeks)Cagrilintide
Most common side effectsNausea and fatigueNausea, vomiting, diarrhea and constipation
Nausea rates11% to 64% across dose groups vs 14% on placebo20% to 47% across dose groups vs 18% on placebo (Phase 2, 26 weeks)
Stopping due to nauseaNot broken out in the Lilly release1.0% vs 0.1% on placebo (REDEFINE 1)
What helpedRaising the dose slowly lowered side effectsSide effects were mostly temporary

The eloralintide side effect rates were published in the Lancet report on the 48-week eloralintide trial. The cagrilintide rates come from its 26-week Phase 2 trial in The Lancet and Novo Nordisk’s REDEFINE 1 cagrilintide results.

The nausea ranges are wide because both trials tested many doses and dosing schedules. For eloralintide, Lilly reported that side effects at the 1 mg and 3 mg doses were similar to placebo. Our post on eloralintide side effects goes through each dose in more detail.

CagriSema vs EloraTZP: The Combination Race

Both companies are pairing their amylin drug with an approved weight loss medicine, and Novo’s combination is further ahead. CagriSema combines cagrilintide with semaglutide, the medicine in Wegovy. EloraTZP combines eloralintide with tirzepatide, the medicine in Zepbound and Mounjaro.

CagriSema vs EloraTZP

DetailCagriSemaEloraTZP
IngredientsCagrilintide plus semaglutideEloralintide plus tirzepatide
Key trialREDEFINE 1 (Phase 3), 3,417 adults without diabetes, 68 weeksPhase 2b, 367 adults with obesity or overweight and type 2 diabetes, 48 weeks
Reported weight loss20.4% vs 3.0% on placeboUp to 23.3%, more than tirzepatide 15 mg alone
Status (October 2026)Under FDA review; decision expected Q4 2026Lilly plans to start Phase 3 in Q4 2026

CagriSema’s results were published in the New England Journal of Medicine REDEFINE 1 trial report, and its FDA timeline comes from Novo Nordisk’s September 2026 CagriSema update. The EloraTZP figures come from Lilly’s EloraTZP Phase 2b results announcement.

These trials enrolled different groups. People with type 2 diabetes usually lose less weight on these medicines than people without diabetes, so EloraTZP’s result and CagriSema’s result are not directly comparable either. Our roundup of new weight loss drugs covers CagriSema and other medicines in development.

What About Petrelintide and Other Amylin Drugs?

Petrelintide is a third once-weekly amylin drug, developed by Zealand Pharma and Roche, and it is also still investigational. In its Phase 2 ZUPREME-1 trial, people lost up to 10.7% of their body weight at 42 weeks compared with 1.7% on placebo, according to Roche’s Phase 2 announcement. Zealand said in September 2026 that its Phase 3 program has started.

Retatrutide also comes up in these discussions, but it is not an amylin drug. Lilly describes it as an investigational triple receptor agonist that acts on GIP, GLP-1 and glucagon receptors. It is not approved and not for sale. You can learn more in our posts on what retatrutide is and retatrutide vs tirzepatide.

Which One Is Closer to Being Available?

Cagrilintide is closer, mainly because of CagriSema. Novo Nordisk filed CagriSema with the FDA in December 2025 and expects a decision in the fourth quarter of 2026. Novo also said it would start a dedicated Phase 3 program for cagrilintide on its own, called RENEW.

Eloralintide is in Phase 3 trials, and Lilly has not announced an FDA filing. Until regulators approve either drug, the only legitimate way to get one is by joining a clinical trial.

SAFETY NOTE

Eloralintide and cagrilintide are not approved medicines. Vials sold online under these names, often labeled “for research use only,” are not FDA-approved drugs, and there is no way to confirm what is in them or how pure they are. Do not inject any product that is not prescribed to you and dispensed by a licensed pharmacy. Our guide on how to spot counterfeit medicines explains the warning signs.

Approved Options You Can Use Now

If you want weight loss treatment now, approved medicines that work through related pathways are available with a prescription. Wegovy (semaglutide) and Zepbound (tirzepatide) are the same medicines that Novo and Lilly are pairing with their amylin drugs. Our Zepbound vs Wegovy comparison explains how they differ.

You can order Wegovy through Pharma Giant, which fills U.S. prescriptions with licensed Canadian pharmacies. Zepbound is also available with a valid prescription.

Whichever medicine you use, get it from a licensed pharmacy, take it exactly as prescribed, and talk with your prescriber before starting, stopping or switching treatment.

Order Wegovy Through Pharma Giant

We fill U.S. prescriptions with licensed Canadian pharmacies. A valid prescription is required.

Order Wegovy

The bottom line

Eloralintide and cagrilintide both copy amylin to help you feel full, but eloralintide targets amylin receptors more selectively. Eloralintide posted the bigger standalone result in its Phase 2 trial, while cagrilintide has more data and is closer to approval as part of CagriSema. Until a head-to-head trial is done, neither can be called better.

If you want treatment today, we, at Pharma Giant, ship Zepbound to the U.S. from licensed Canadian pharmacies with a valid prescription, and your prescriber can help you decide whether Zepbound or Wegovy fits your needs.

Get Zepbound Through Pharma Giant

We ship Zepbound to the U.S. from licensed Canadian pharmacies with a valid prescription.

Order Zepbound

Frequently Asked Questions

No one knows yet. Eloralintide’s best Phase 2 result (20.1% at 48 weeks) was higher than cagrilintide’s best standalone result (11.8% at 68 weeks), but the trials used different doses, lengths and designs. Only a head-to-head trial could answer this question.
No. Eloralintide is a selective amylin receptor agonist. It copies the hormone amylin and does not act on GLP-1 receptors like semaglutide does. Cagrilintide is not a GLP-1 drug either.
No. Cagrilintide is one drug, an amylin analog. CagriSema is a once-weekly combination of cagrilintide and semaglutide. Neither is approved as of October 28, 2026.
Petrelintide is an investigational once-weekly amylin drug from Zealand Pharma and Roche. It led to up to 10.7% weight loss at 42 weeks in its Phase 2 trial and is now in Phase 3.
The newest FDA-approved weight loss drug in 2026 is Foundayo (orforglipron), a once-daily GLP-1 pill that the FDA approved on April 1, 2026. Our Foundayo dosing schedule guide explains how it is taken. Amylin drugs such as eloralintide and cagrilintide are still in trials.
No. Neither drug is approved or sold by licensed pharmacies. Products sold online under these names are not approved medicines and may not contain what the label says. We, at Pharma Giant, are following the eloralintide trials closely. If it is approved by Health Canada and becomes available through the licensed Canadian pharmacies we work with, we plan to look into adding it to our catalog. Until then, check back on our blog for updates as new trial results come out.
  1. Eli Lilly and Company. Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. November 6, 2025. View source
  2. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631-2643. PMID 41207310. View source
  3. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. PMID 41109426. View source
  4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160-2172. PMID 34798060. View source
  5. Novo Nordisk. Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme. September 16, 2025. View source
  6. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025;393:635-647. PMID 40544433. View source
  7. Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. December 18, 2025. View source
  8. Novo Nordisk. Novo’s CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. September 21, 2026. View source
  9. Eli Lilly and Company. Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes. September 30, 2026. View source
  10. Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity. March 5, 2026. View source
  11. Zealand Pharma. Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology. September 29, 2026. View source
  12. Eli Lilly and Company. Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026. September 15, 2026. View source
  13. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026. View source
Last updated: October 28, 2026